Business Description

SILO Pharma Inc
NAICS : 541713
SIC : 8731
ISIN : US73052R1041
Description
SILO Pharma Inc is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company is engaged in developing innovative solutions to address a variety of underserved conditions which includes Alzheimer's; Parkinson's; Multiple Sclerosis (MS); Rheumatoid Arthritis (RA); and Stress-Induced Psychiatric Disorders.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.81 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -0.03 | |||||
Beneish M-Score | -3.99 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -28.4 | |||||
3-Year EBITDA Growth Rate | 5.5 | |||||
3-Year EPS without NRI Growth Rate | 5.1 | |||||
3-Year FCF Growth Rate | 3.3 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 21.83 | |||||
9-Day RSI | 28 | |||||
14-Day RSI | 32.87 | |||||
6-1 Month Momentum % | -2.02 | |||||
12-1 Month Momentum % | -60.25 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.09 | |||||
Quick Ratio | 9.09 | |||||
Cash Ratio | 8.92 | |||||
Days Payable | 44749 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -88.4 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 94.44 | |||||
Operating Margin % | -6283.33 | |||||
Net Margin % | -6340.28 | |||||
ROE % | -47.74 | |||||
ROA % | -41.49 | |||||
ROIC % | -2110.07 | |||||
ROC (Joel Greenblatt) % | -1776.58 | |||||
ROCE % | -45.83 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 62.59 | |||||
PB Ratio | 0.63 | |||||
Price-to-Tangible-Book | 0.63 | |||||
EV-to-EBIT | 0.99 | |||||
EV-to-EBITDA | 0.99 | |||||
EV-to-Revenue | -65.75 | |||||
EV-to-FCF | 1.33 | |||||
Price-to-Net-Current-Asset-Value | 0.63 | |||||
Price-to-Net-Cash | 0.65 | |||||
Earnings Yield (Greenblatt) % | 101.01 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SILO
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
SILO Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0.072 | ||
EPS (TTM) ($) | -1.68 | ||
Beta | 1.69 | ||
Volatility % | 34.44 | ||
14-Day RSI | 32.87 | ||
14-Day ATR ($) | 0.115213 | ||
20-Day SMA ($) | 1.90777 | ||
12-1 Month Momentum % | -60.25 | ||
52-Week Range ($) | 1.64 - 6.56 | ||
Shares Outstanding (Mil) | 3.11 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
SILO Pharma Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
SILO Pharma Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
SILO Pharma Inc Frequently Asked Questions
What is SILO Pharma Inc(SILO)'s stock price today?
The current price of SILO is $1.68. The 52 week high of SILO is $6.56 and 52 week low is $1.64.
When is next earnings date of SILO Pharma Inc(SILO)?
The next earnings date of SILO Pharma Inc(SILO) is .
Does SILO Pharma Inc(SILO) pay dividends? If so, how much?
SILO Pharma Inc(SILO) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |